ACS NEWS ▸ AbbVie hosts Pharma Leaders Conference
36
C&EN | CEN.ACS.ORG | JANUARY 16, 2017
The 2016 class of SciFinder Future Leaders.
Apply to be a SciFinder Future Leader Applications are being accepted for the 2017 SciFinder Future Leaders program, organized by CAS, a division of the American Chemical Society. The program will be held Aug. 14–19 in Columbus, Ohio. The program provides Ph.D. students and postdoctoral researchers from around the world with opportunities to collaborate with CAS scientists, innovators, and business leaders to expand their professional network and build connections. At the conclusion of the program in Columbus, participants will attend the fall ACS national meeting in Washington, D.C., from Aug. 20–24. “Participation in the SciFinder Future Leaders program gave me the opportunity to find out the inner workings of CAS and how I can better use SciFinder to improve my approach to research,” says Banothile Makhubela, a senior lecturer in chemistry at the University of Johannesburg, in South Africa, who participated in the program in 2013. “We were also able to offer our advice on exciting developmental projects, helping CAS deliver the next generation of online research tools for chemists,” says Marc Reid, who participated in the program in 2016 as a postdoc and is now a Leverhulme Trust Fellow and Strathclyde-GSK Early Career Academic at the University of Strathclyde in Glasgow, Scotland. Nadine Borduas, a graduate student in chemistry at ETH Zürich, who participated in the program in 2014, says that “taking a short break from my Ph.D. research to attend the program and the ACS meeting gave me a huge boost of energy to move forward in my own research. I met like-minded students and postdocs that were excited about science and willing to learn new things.” “Because it’s not only a prize but an educational program, you get to visit research centers around Columbus,” says Fernando Gomollón-Bel, who attended in 2014 while he was a graduate student at the Institute of Chemical Synthesis & Homogeneous Catalysis in Spain. “I remember quite vividly the amazing facilities of Battelle and the very interesting mix of ideas we learned from all the start-ups growing in TechColumbus (now Rev1 Ventures). As a Ph.D. student, I appreciated seeing opportunities in all different kinds of markets.” The deadline to apply for the 2017 program is Feb. 12. For more information, visit www.cas.org/futureleaders.—LINDA WANG
presenters discussed predictive science topics, including possible precompetitive collaborations to address toxicity challenges encountered in discovering and developing new drugs. At the close of the conference, attendees created a list of actions and timelines aimed at addressing the proposed precompetitive collaborations forged or strengthened during the event. As a neutral third-party convener, ACS will help
facilitate these post-conference activities. “ACS is committed to collaborating with the pharma industry to support the development of critical therapies and cures aimed at challenging diseases and other health issues,” said Vijay Kuruganti, director of Industry Member Programs. The next Pharma Leaders Conference will be hosted by Johnson & Johnson at its Spring House, Pa., site Oct. 19–20.—
SUSAN J. AINSWORTH, special to C&EN
CREDIT: CAS
For the 14th consecutive year, the ACS Pharma Leaders Conference brought together the pharmaceutical and biotechnology industries’ chemistry research leaders to discuss issues of common concern. Executives representing about two dozen companies were invited to attend the meeting, which was held Oct. 13–14, 2016, at AbbVie’s North Chicago, Ill., facility. Co-organized by ACS Industry Member Programs and AbbVie, this year’s meeting was again aimed at exploring areas of mutual interest with the goal of accelerating drug development. Phillip R. Kym, AbbVie’s director of chemistry, crafted an agenda focused on three themes: neglected diseases, predictive science, and precompetitive and noncompetitive chemistry collaborations. ACS Past President Diane Grob Schmidt and AbbVie Vice President of Discovery James P. Sullivan presented remarks to kick off the conference. Peter Warner, senior program officer at the Bill & Melinda Gates Foundation, provided the keynote address, “Neglected Diseases—What are they and what can we do about them?” He focused on the foundation’s work and its interactions with pharmaceutical company collaborators. Other presentations featured case studies about pharma-assisted drug discovery targeted at neglected tropical diseases. They described partnerships with groups including the Drugs for Neglected Diseases initiative and the Anti-Wolbachia Consortium, and highlighted company-led programs that enable employees or retirees to volunteer to develop therapies to treat neglected diseases. The group presented updates on precompetitive efforts launched at the 2015 Pharma Leaders conference, which included sharing chemical building blocks and annotated compound sets or tool compounds—highly selective chemical probes that help researchers determine the biological function of a given target. They also returned to a discussion of ways to promote the development and use of computer-aided drug design (CADD) tools. Some emphasized the impending shortage of computational chemists dedicated to drug discovery and development as cream-of-the crop candidates are lured to other industries and pioneers in the discipline retire. Tackling a session titled, “Medicinal Chemistry Lessons for 2016 and Beyond,”
